Cipla subsidiary Invagen signs partnership with Qilu on biosimilar licensing
Invagen Pharmaceuticals, a wholly owned subsidiary of Cipla, announced a strategic partnership with Qilu for the licensing and supply of a biosimilar to Keytruda (pembrolizumab) in the US.
Story updates
04:47:00 PM UTC
SquawkNews
Drug firm Cipla Ltd on Thursday (September 3) announced that its wholly owned subsidiary Invagen Pharmaceuticals Inc has entered into a strategic partnership with Qilu Pharmaceutical Co. Ltd for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), in the United St…
Drug firm Cipla Ltd on Thursday (September 3) announced that its wholly owned subsidiary Invagen Pharmaceuticals Inc has entered into a strategic partnership with Qilu Pharmaceutical Co.
Ltd for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), in the United St…